RCS - Surgical Innovations - Product launch for Cellis Breast

Surgical InnovationsAnnouncement

02/12/2020 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201202:nRSB1758Ha&default-theme=true

RNS Number : 1758H  Surgical Innovations Group PLC  02 December 2020

Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")

 

Product launch for Cellis Breast

 

Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and
distributor of innovative medical technology for minimally invasive surgery,
announces that its wholly owned subsidiary, Elemental Healthcare Ltd
("Elemental"), has successfully launched the new biological matrix range for
Breast Reconstruction, manufactured by Meccellis.

 

Cellis Breast is a comprehensive range of biological matrices for Breast
Reconstruction which received their CE mark in April 2020. Trials were delayed
as a consequence of the NHS response to Covid-19; however with the resumption
in some hospitals of breast reconstruction, evaluations have been successfully
carried out which has meant the Company has met its Q4 target for UK market
launch of the product.

 

Elemental's Project Management team worked with key surgeons at selected
hospitals to understand optimal practice and techniques. This product
knowledge has been shared with the wider sales team and Elemental now has a
number of accounts at the later stages of evaluation and purchasing.

 

The UK market for biological matrices for breast reconstruction is worth
approximately £16 million and Cellis Breast is well placed to gain market
share as reconstructive surgery resumes following deferrals due to Covid-19.

 

Adam Power, Elemental MD and Group Development Director at SI, said:
"Elemental have worked closely with Meccellis over the last three years during
the development of Cellis Breast and we are excited that we now have a range
of products that are well designed and competitively priced which will enable
us to compete well in this market."

 

Anthony Peres, CEO of Meccellis, commented: "The UK is one of the largest
markets in the world for the use of biological matrix products in immediate
breast reconstruction following cancer surgery. Meccellis now has a full
range of products for this procedure that are both innovative and cost
effective. Following the successful evaluations, we are now looking forward to
the further success of our partner, Elemental Healthcare, in growing UK
sales."

 

For further information please contact:

 

 Surgical Innovations Group plc                       www sigroupplc com (http://www.sigroupplc.com/)
 David Marsh, CEO                                     Tel: 0113 230 7597
 Charmaine Day, Co Sec & GFC

 N+1 Singer (Nominated Adviser & Broker)              Tel: 020 7496 3000
 Aubrey Powell (Corporate Finance)
 Rachel Hayes (Corporate Broking)

 Walbrook PR (Financial PR & Investor Relations)      Tel: 020 7933 8780 or si@walbrookpr.com (mailto:si@walbrookpr.com)
 Paul McManus / Lianne Cawthorne                      Mob: 07980 541 893 / 07584 391 303

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFSIFMFESSESE